AU1348895A - Use of a tricyclic compound for obtaining medicinal products intended for the treatment of memory/cognitive disorders - Google Patents

Use of a tricyclic compound for obtaining medicinal products intended for the treatment of memory/cognitive disorders

Info

Publication number
AU1348895A
AU1348895A AU13488/95A AU1348895A AU1348895A AU 1348895 A AU1348895 A AU 1348895A AU 13488/95 A AU13488/95 A AU 13488/95A AU 1348895 A AU1348895 A AU 1348895A AU 1348895 A AU1348895 A AU 1348895A
Authority
AU
Australia
Prior art keywords
memory
treatment
cognitive disorders
medicinal products
tricyclic compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU13488/95A
Other versions
AU684880B2 (en
Inventor
Bruno Delalleau
Antoine Deslandes
Annie Kamoun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADIR SARL
Original Assignee
ADIR SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADIR SARL filed Critical ADIR SARL
Publication of AU1348895A publication Critical patent/AU1348895A/en
Application granted granted Critical
Publication of AU684880B2 publication Critical patent/AU684880B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AU13488/95A 1994-02-25 1995-02-24 Use of a tricyclic compound for obtaining medicinal products intended for the treatment of memory/cognitive disorders Ceased AU684880B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9402160 1994-02-25
FR9402160A FR2716623B1 (en) 1994-02-25 1994-02-25 Use of a tricyclic derivative for obtaining medicaments intended for the treatment of mnemo-cognitive disorders.

Publications (2)

Publication Number Publication Date
AU1348895A true AU1348895A (en) 1995-09-07
AU684880B2 AU684880B2 (en) 1998-01-08

Family

ID=9460422

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13488/95A Ceased AU684880B2 (en) 1994-02-25 1995-02-24 Use of a tricyclic compound for obtaining medicinal products intended for the treatment of memory/cognitive disorders

Country Status (10)

Country Link
EP (1) EP0671173A1 (en)
JP (1) JPH07258089A (en)
CN (1) CN1051226C (en)
AU (1) AU684880B2 (en)
CA (1) CA2143251A1 (en)
FI (1) FI950725A (en)
FR (1) FR2716623B1 (en)
NO (1) NO950714L (en)
NZ (1) NZ270566A (en)
ZA (1) ZA951575B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777616B2 (en) * 2000-03-31 2004-10-21 Les Laboratoires Servier New process for the preparation of 11-amino-3-chloro-6,11- dihydro-5,5-dioxo-6-methyl-dibenzo(c,f)(1,2)thiazepine and application to the synthesis of tianeptine

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2747921B1 (en) * 1996-04-24 1998-10-30 Adir MATRIX TABLET FOR THE EXTENDED RELEASE OF TIANEPTINE SODIUM SALT AFTER ORAL ADMINISTRATION
FR2791891A1 (en) * 1999-04-07 2000-10-13 Adir USE OF TIANEPTINE FOR OBTAINING MEDICINES FOR THE TREATMENT OF NEURODEGENERESCENCE CONDITIONS
US8367656B2 (en) * 2007-03-05 2013-02-05 Janssen Biotech, Inc. Polymorphs of 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S dioxide and methods of making and using the same
US8198268B2 (en) 2008-10-31 2012-06-12 Janssen Biotech, Inc. Tianeptine sulfate salt forms and methods of making and using the same
WO2010070667A2 (en) * 2008-11-19 2010-06-24 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of 7-((3-chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2) thiazepin-11-yl)amino)heptanoate
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
KR102199871B1 (en) 2018-12-21 2021-01-08 주식회사 한서켐 A process for preparing 3,11-Dichloro-6-methyl -6,11-dihydrodibenzo[c,f][1,2]thiazepine 5,5-dioxide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1269551A (en) 1969-03-27 1972-04-06 Science Union & Cie New tricyclic derivatives and process for their manufacture
CH629667A5 (en) * 1978-03-28 1982-05-14 Science Union & Cie PHARMACEUTICAL COMPOSITION ACTING ON GASTROINTESTINAL MOTORITY.
FR2635461B1 (en) * 1988-08-18 1992-01-17 Adir USE OF TRICYCLIC DERIVATIVES FOR OBTAINING MEDICINES FOR TREATING STRESS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777616B2 (en) * 2000-03-31 2004-10-21 Les Laboratoires Servier New process for the preparation of 11-amino-3-chloro-6,11- dihydro-5,5-dioxo-6-methyl-dibenzo(c,f)(1,2)thiazepine and application to the synthesis of tianeptine

Also Published As

Publication number Publication date
CA2143251A1 (en) 1995-08-26
FI950725A (en) 1995-08-26
NZ270566A (en) 1996-01-26
NO950714D0 (en) 1995-02-24
FR2716623A1 (en) 1995-09-01
CN1119100A (en) 1996-03-27
AU684880B2 (en) 1998-01-08
CN1051226C (en) 2000-04-12
JPH07258089A (en) 1995-10-09
EP0671173A1 (en) 1995-09-13
FR2716623B1 (en) 1996-08-23
ZA951575B (en) 1995-12-12
NO950714L (en) 1995-08-28
FI950725A0 (en) 1995-02-17

Similar Documents

Publication Publication Date Title
HK1008180A1 (en) Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
AU3548795A (en) Benzopyranopyrazolyl derivatives for the treatment of inflammation
IL116998A0 (en) Novel indoline compounds processes for their preparation and their use for the treatment of CNS disorders
AU2109195A (en) Two-component device for the administration of drugs
HRP950483B1 (en) New pharmaceutical product
HUP9904525A3 (en) Pharmaceutical compositions for the treatment of neurological disorders comprising s-(-)-n-propargyl-1-amino indan
NO306977B1 (en) Use of thienol [1,5] benzodiazepine for the treatment of gastrointestinal disorders
HK1041489A1 (en) 5-0-Desosaminyl 6-0-methylerythronolide a for use for the preparation of bilogically-active products
AU2388895A (en) Substituted cyclopentadienyl compounds for the treatment of inflammation
AU5802196A (en) Use of bis-1,2,4-triazoles for the manufacture of a medicament for the treatment of cancers
GB2292079B (en) Coated prednisolone preparation for the treatment of inflamatory bowel disease
AU2508597A (en) Drug for the treatment of tumours
AU2424895A (en) Substituted spirodienes for the treatment of inflammation
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
AU3187595A (en) Compounds for the treatment of restenosis
AU1348895A (en) Use of a tricyclic compound for obtaining medicinal products intended for the treatment of memory/cognitive disorders
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
AU2739497A (en) Use of vitamin d analogs for the treatment of arthritic disease
AU6369396A (en) Drug for ameliorating brain diseases
IL121329A0 (en) A pharmaceutical composition for the treatment of cancer
AUPM456894A0 (en) Treatment for gastric disorders
AU4081393A (en) Medicaments for the treatment of anxiety
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
ZA945651B (en) Use of benzenesulphonzlindole derivatives for the preparation of medicines
PL325203A1 (en) Polymorphs of the precursor of the drug 6-n-(l-ala-l-ala)-throwafloxacin

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired